TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors

Colleen S. Sinclair, Camilo Adem, Ali Naderi, Cheryl L. Soderberg, Michele Johnson, Kangjian Wu, Linda Wadum, Vicki L. Couch, Thomas A. Sellers, Daniel Schaid, Jeffrey Slezak, Zach Fredericksen, James N. Ingle, Lynn Hartmann, Robert B. Jenkins, Fergus J. Couch

Research output: Contribution to journalArticlepeer-review

77 Scopus citations


The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRC1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.

Original languageEnglish (US)
Pages (from-to)3587-3591
Number of pages5
JournalCancer research
Issue number13
StatePublished - Jul 1 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors'. Together they form a unique fingerprint.

Cite this